Bisphosphonate therapy in fibrous dysplasia. Conference Paper uri icon



  • Fibrous dysplasia is proliferation of fibrous tissue within the bone marrow causing osteolytic lesions and pathologic fractures. Recently, second generation bisphosphonates have shown promise in the treatment of patients with fibrous dysplasia. In the current study, six patients with fibrous dysplasia were treated with either oral alone or oral and intravenous bisphosphonates. The participants were observed for changes in N-telopeptide, pain score, and radiographic changes. In the current study, the combination bisphosphonate therapy diminished pain, prevented fractures, lowered N-telopeptide values, and led to partial resolution of fibrous dysplasia lesions.

publication date

  • January 1, 2001



  • Alendronate
  • Diphosphonates
  • Fibrous Dysplasia of Bone


Scopus Document Identifier

  • 0035167714

PubMed ID

  • 11154006

Additional Document Info


  • 382